Triple combination therapy for clinically nonmetastatic super-high-risk prostate cancer.

Koji YoshimuraKei MuraokaMichiko FukasawaMika FukushimaMasatoshi KumagaiRyo YabusakiMasakatsu UedaYusuke ShiraishiMasaaki Imamura

Published in: IJU case reports (2022)

Triple combination therapy may be an option for super-high-risk, nonmetastatic prostate cancer.

Keyphrases